Kratom-derived opioids face federal restrictions amid research concerns

Federal authorities have placed three laboratory-modified opioids derived from kratom—MGPI, MGM-15, and MGM-16—into Schedule I of the Controlled Substances Act. While the U.S. Department of Justice and Drug Enforcement Administration identified these compounds as posing significant risks of addiction and respiratory depression, researchers at Rutgers Health warn that such restrictions could hinder medical studies into treatments for pain and opioid dependence.

Experts emphasize a distinction between traditional botanical kratom and highly concentrated or chemically modified products, such as those containing 7-hydroxymitragynine (7-OH). These concentrated formulations can produce different physiological effects and may lead to increased tolerance and physical dependence.

Kratom withdrawal symptoms typically emerge within the first few days and may include fluctuations in mood, sleep, energy, and concentration. While some individuals may attempt to taper their usage, medical professionals suggest that heavy or long-term use, particularly involving concentrated extracts, may require medically supervised detoxification to manage symptoms safely.